LTR Pharma Strengthens U.S. Market Strategy Through New Commercial Partnership
LTR Pharma Limited (ASX: LTP) has reinforced its U.S. commercialisation strategy by entering into a definitive agreement with telehealth company Shed, creating a structured pathway for the launch of its flagship erectile dysfunction therapy, ROXUS®. The long-form agreement formalises the relationship between the two companies and outlines collaboration across product marketing, distribution, branding and operational execution. As part of the arrangement, Shed has committed to facilitating the delivery of at least 150,000 ROXUS units during the first year after commercial launch, highlighting strong confidence in anticipated patient demand.
Through the partnership, LTR Pharma will gain immediate access to Shed's established telehealth ecosystem, including its digital platform, prescribing network and customer acquisition capabilities. This approach is expected to accelerate market entry while reducing execution risk and infrastructure costs. With pre-launch activities already underway and patient registrations commencing, the company is positioning ROXUS for a scalable U.S. rollout while continuing to expand its international commercial footprint and long-term growth opportunities.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
LTR Pharma Strengthens U.S. Market Strategy Through New Commercial Partnership
LTR Pharma Limited (ASX: LTP) has reinforced its U.S. commercialisation strategy by entering into a definitive agreement with telehealth company Shed, creating a structured pathway for the launch of its flagship erectile dysfunction therapy, ROXUS®. The long-form agreement formalises the relationship between the two companies and outlines collaboration across product marketing, distribution, branding and operational execution. As part of the arrangement, Shed has committed to facilitating the delivery of at least 150,000 ROXUS units during the first year after commercial launch, highlighting strong confidence in anticipated patient demand.
Through the partnership, LTR Pharma will gain immediate access to Shed's established telehealth ecosystem, including its digital platform, prescribing network and customer acquisition capabilities. This approach is expected to accelerate market entry while reducing execution risk and infrastructure costs. With pre-launch activities already underway and patient registrations commencing, the company is positioning ROXUS for a scalable U.S. rollout while continuing to expand its international commercial footprint and long-term growth opportunities.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au